XML 75 R15.htm IDEA: XBRL DOCUMENT
v3.21.2

STOCK OPTION AND BENEFIT PLANS | 12 Months Ended
--- | ---
Jul. 03, 2021
Share-based Payment Arrangement [Abstract] |
STOCK OPTION AND BENEFIT PLANS | STOCK OPTION AND BENEFIT PLANS The Company’s incentive plan provides for equity and liability awards to employees and non-employee directors in the form of stock options, stock appreciation rights (SARs), restricted stock, restricted stock units, stock awards, stock units, performance shares, performance units, and other stock-based or cash-based awards. Compensation cost is recognized on a straight-line basis over the requisite employee service period, which is generally the vesting period, and is recorded as employee compensation expense in cost of goods sold, research, development and engineering, and selling, general and administrative expenses. Share-based compensation is recognized only for those awards that are expected to vest, with forfeitures estimated at the date of grant based on historical experience and future expectations. In addition to service conditions, these SARs contain a performance condition. The additional performance condition is based upon the achievement of Return on Invested Capital (ROIC) goals relative to a peer group. All awards with performance conditions are measured over the vesting period and are charged to compensation expense over the requisite service period based on the number of shares expected to vest. The SARs cliff vest after a three-year period from date of grant and expire five years from date of grant. On July 23, 2020, the Company granted 155,000 SARs under the 2010 Incentive Plan to certain key employees and outside directors at a strike price of $6.94 and a grant date fair value of $2.32. As of July 3, 2021, 150,000 remain outstanding. The grant date fair value for the awards granted during fiscal year 2021, were estimated using the Black Scholes option valuation method with the following weighted average assumptions as of July 23, 2020:
| Fiscal Year 2021
| July 23, 2020
Expected dividend yield | —%
Risk – free interest rate | 0.17%
Expected volatility | 42.85%
Expected life | 4.00
On July 26, 2019, the Company granted 175,000 SARs under the 2010 Incentive Plan to certain key employees and outside directors at a strike price of $4.93 and a grant date fair value of $1.23. As of July 3, 2021, 140,000 remain outstanding. The grant date fair value for the awards granted during fiscal year 2020, were estimated using the Black Scholes option valuation method with the following weighted average assumptions as of July 26, 2019:
| Fiscal Year 2020
| July 26, 2019
Expected dividend yield | —%
Risk – free interest rate | 1.54%
Expected volatility | 28.50%
Expected life | 4.00
On July 27, 2018, the Company granted 161,250 SARs under the 2010 Incentive Plan to certain key employees and outside directors at a strike price of $8.17 and a grant date fair value of $2.27. As of July 3, 2021, 116,250 remain outstanding. The grant date fair value for the awards granted during fiscal year 2019, were estimated using the Black Scholes option valuation method with the following weighted average assumptions as of July 27, 2018:
| Fiscal Year 2019
| July 27, 2018
Expected dividend yield | —%
Risk – free interest rate | 2.80%
Expected volatility | 29.75%
Expected life | 4.00
Subsequent to July 3, 2021, the Company granted 165,000 SARs with a strike price of $7.17 and a grant date fair value of $2.73. Share-based compensation expense is recognized only for those awards that are expected to vest, with forfeitures estimated at the date of grant based on the Company’s historical experience and future expectations. This forfeiture rate will be revised, if necessary, in subsequent periods if actual forfeitures differ from the amount estimated. Share-based compensation expense for fiscal years ended July 3, 2021, June 27, 2020 and June 29, 2019 was $0.2 million, $0.3 million and $0.4 million, respectively. The Black-Scholes option valuation model is used by the Company for estimating the fair value of SARs. Option valuation models require the input of highly subjective assumptions, particularly for the expected term and expected stock price volatility. Changes in these assumptions can materially affect the fair value estimates. There were 20,000 SARs exercised with an immaterial amount of intrinsic value in fiscal year 2021. There were no SARs exercised during fiscal year 2020 or 2019. As of July 3, 2021, total unrecognized compensation expense related to nonvested share-based compensation arrangements was approximately $0.3 million. This expense is expected to be recognized over a weighted-average period of 1.81 years. The following table summarizes the Company’s Options and SARs activity for all plans from July 1, 2018 through July 3, 2021:
| SARs Available For Grant |  | SARs Outstanding |  | Aggregate Intrinsic Value (in thousands) |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Life (in years)
Balances, July 1, 2018 | 404,335 |  |  | 1,074,999 |  |  | $ | 79 |  |  | $ | 8.90 |  |  | 2.3
Shares authorized | — |  |  |  |  |  |  | — |  |  |
SARs granted | (161,250) |  |  | 161,250 |  |  |  |  | 8.17 |  |  |
SARs forfeited | 250,833 |  |  | (250,833) |  |  |  |  | 10.59 |  |  |
SARs exercised | — |  |  | — |  |  | — |  |  | — |  |  |
Balances June 30, 2019 | 493,918 |  |  | 985,416 |  |  | $ | — |  |  | $ | 8.35 |  |  | 1.7
Shares authorized | — |  |  |  |  |  |  | — |  |  |
SARs granted | (175,000) |  |  | 175,000 |  |  |  |  | 4.93 |  |  |
SARs forfeited | 290,833 |  |  | (290,833) |  |  |  |  | 7.71 |  |  |
SARs exercised | — |  |  | — |  |  | — |  |  | — |  |  |
Balances, June 27, 2020 | 609,751 |  |  | 869,583 |  |  | $ | — |  |  | $ | 7.87 |  |  | 1.9
Shares authorized | — |  |  |  |  |  |  | — |  |  |
SARs granted | (155,000) |  |  | 155,000 |  |  |  |  | 6.94 |  |  |
SARs forfeited | 213,333 |  |  | (213,333) |  |  |  |  | 9.88 |  |  |
SARs exercised | 20,000 |  |  | (20,000) |  |  | — |  |  | 7.72 |  |  |
Balances, July 3, 2021 | 688,084 |  |  | 791,250 |  |  | $ | — |  |  | $ | 7.15 |  |  | 1.9
Exercisable at July 3, 2021 |  |  | 385,000 |  |  | $ | — |  |  | $ | 7.73 |  |  | 0.6
Additional information regarding SARs outstanding and exercisable as of July 3, 2021, is as follows:
Range of Exercise Prices |  | Number Outstanding |  | Weighted Avg. Remaining Contractual Life (yrs.) |  | Weighted Avg. Exercise Price |  | Number Exercisable |  | Weighted Avg. Exercise Price
$4.40 – $7.90 |  | 477,500 |  |  | 2.6 |  | $ | 6.48 |  |  | 187,500 |  |  | $ | 7.26 |
7.91 – 9.91 |  | 313,750 |  |  | 0.3 |  | 8.17 |  |  | 197,500 |  |  | 8.17 |
$4.40 to $11.34 |  | 791,250 |  |  | 1.9 |  | $ | 7.15 |  |  | 385,000 |  |  | $ | 7.73 |
The Company has defined contribution plans available to U.S. employees who have attained age 21. Company contributions to the plans were approximately $0.9 million, $0.8 million, and $0.9 million during fiscal years 2021, 2020 and 2019, respectively.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration